Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ALLO
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 21, 2026 | Geoffrey M. Parker CHIEF FINANCIAL OFFICER | ALLO Allogene Therapeutics, Inc. | Sale | 36,342 | $1.34 | $48.7K Sale | Form 4 ↗ |
| Aug 21, 2026 | Earl Martin Douglas SVP, General Counsel | ALLO Allogene Therapeutics, Inc. | Sale | 29,697 | $2.12 | $63.0K Sale | Form 4 ↗ |
| Apr 21, 2026 | Annie Yoshiyama SVP, Finance | ALLO Allogene Therapeutics, Inc. | Sale | 9,586 | $2.31 | $22.1K Sale | Form 4 ↗ |
| Mar 31, 2026 | Benjamin Machinas Beneski SVP, Chief Technical Officer | ALLO Allogene Therapeutics, Inc. | Sale | 2,867 | $2.50 | $7,168 Sale | Form 4 ↗ |
| Mar 16, 2026 | Benjamin Machinas Beneski SVP, Chief Technical Officer | ALLO Allogene Therapeutics, Inc. | Sale | 4,835 | $2.47 | $11.9K Sale | Form 4 ↗ |
| Mar 16, 2026 | David D. Chang President and CEO, Director | ALLO Allogene Therapeutics, Inc. | Sale | 47,763 | $2.47 | $118.0K Sale | Form 4 ↗ |
| Mar 2, 2026 | Benjamin Machinas Beneski SVP, Chief Technical Officer | ALLO Allogene Therapeutics, Inc. | Sale | 7,132 | $2.60 | $18.5K Sale | Form 4 ↗ |
| Feb 2, 2026 | Benjamin Machinas Beneski SVP, Chief Technical Officer | ALLO Allogene Therapeutics, Inc. | Sale | 7,549 | $1.73 | $13.1K Sale | Form 4 ↗ |
| Feb 2, 2026 | David D. Chang President and CEO, Director | ALLO Allogene Therapeutics, Inc. | Sale | 95,269 | $1.80 | $171.5K Sale | Form 4 ↗ |
| Feb 2, 2026 | Geoffrey M. Parker CHIEF FINANCIAL OFFICER | ALLO Allogene Therapeutics, Inc. | Sale | 24,001 | $1.76 | $42.2K Sale | Form 4 ↗ |
| Feb 2, 2026 | Annie Yoshiyama SVP, Finance | ALLO Allogene Therapeutics, Inc. | Sale | 4,167 | $1.72 | $7,167 Sale | Form 4 ↗ |
| Feb 2, 2026 | Zachary Roberts EVP of R&D | ALLO Allogene Therapeutics, Inc. | Sale | 35,700 | $1.77 | $63.2K Sale | Form 4 ↗ |
| Feb 2, 2026 | Earl Martin Douglas SVP, General Counsel | ALLO Allogene Therapeutics, Inc. | Sale | 22,900 | $1.76 | $40.3K Sale | Form 4 ↗ |
| Jan 21, 2026 | Zachary Roberts EVP of R&D | ALLO Allogene Therapeutics, Inc. | Sale | 26,269 | $1.56 | $41.0K Sale | Form 4 ↗ |
| Nov 17, 2025 | Benjamin Machinas Beneski SVP, Chief Technical Officer | ALLO Allogene Therapeutics, Inc. | Sale | 786 | $1.22 | $959 Sale | Form 4 ↗ |
| Oct 21, 2025 | Geoffrey M. Parker CHIEF FINANCIAL OFFICER | ALLO Allogene Therapeutics, Inc. | Sale | 36,744 | $1.26 | $46.3K Sale | Form 4 ↗ |
| Jun 10, 2025 | Deborah M. Messemer Director | ALLO Allogene Therapeutics, Inc. | Sale | 36,885 | $1.42 | $52.4K Sale | Form 4 ↗ |
| Apr 21, 2025 | Annie Yoshiyama SVP, Finance | ALLO Allogene Therapeutics, Inc. | Sale | 9,601 | $1.41 | $13.5K Sale | Form 4 ↗ |
| Mar 14, 2025 | David D. Chang President and CEO, Director | ALLO Allogene Therapeutics, Inc. | Sale | 46,668 | $1.96 | $91.5K Sale | Form 4 ↗ |
| Mar 14, 2025 | Benjamin Machinas Beneski SVP, Chief Technical Officer | ALLO Allogene Therapeutics, Inc. | Sale | 5,488 | $1.98 | $10.9K Sale | Form 4 ↗ |
| Feb 18, 2025 | Deborah M. Messemer Director | ALLO Allogene Therapeutics, Inc. | Sale | 13,313 | $2.43 | $32.4K Sale | Form 4 ↗ |
| Feb 3, 2025 | Earl Martin Douglas SVP, General Counsel | ALLO Allogene Therapeutics, Inc. | Sale | 6,404 | $1.71 | $11.0K Sale | Form 4 ↗ |
| Feb 3, 2025 | Geoffrey M. Parker CHIEF FINANCIAL OFFICER | ALLO Allogene Therapeutics, Inc. | Sale | 4,361 | $1.73 | $7,545 Sale | Form 4 ↗ |
| Feb 3, 2025 | Timothy L. Moore Chief Technical Officer | ALLO Allogene Therapeutics, Inc. | Sale | 14,746 | $1.71 | $25.2K Sale | Form 4 ↗ |
| Feb 3, 2025 | David D. Chang President and CEO, Director | ALLO Allogene Therapeutics, Inc. | Sale | 46,003 | $1.68 | $77.3K Sale | Form 4 ↗ |
| Feb 3, 2025 | Zachary Roberts EVP of R&D | ALLO Allogene Therapeutics, Inc. | Sale | 18,832 | $1.70 | $32.0K Sale | Form 4 ↗ |
| Jan 21, 2025 | Zachary Roberts EVP of R&D | ALLO Allogene Therapeutics, Inc. | Sale | 27,199 | $1.78 | $48.4K Sale | Form 4 ↗ |
| Dec 9, 2024 | Deborah M. Messemer Director | ALLO Allogene Therapeutics, Inc. | Sale | 9,136 | $2.18 | $19.9K Sale | Form 4 ↗ |
| Dec 5, 2024 | Franz B. Humer Director | ALLO Allogene Therapeutics, Inc. | Sale | 9,221 | $2.16 | $19.9K Sale | Form 4 ↗ |
29 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:03 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances